MSC-L

MSC-L is an engineered cell therapy product consisting of human umbilical cord-derived allogenic mesenchymal stem cells (MSCs) that have been genetically modified to express an antitumor CXCL-family chemokine and a TNF-superfamily co-stimulatory molecule. Developed by Shanghai East Hospital for the treatment of advanced colorectal cancer, MSC-L is designed to leverage the natural tumor-homing capabilities of MSCs to deliver therapeutic proteins directly into the tumor microenvironment. The expressed chemokines are intended to recruit peripheral T cells and natural killer (NK) cells to the tumor, while the co-stimulatory molecules provide the necessary signals to activate these infiltrated lymphocytes, thereby promoting a robust and persistent antitumor immune response. This strategy is particularly aimed at treating "cold" tumors with unfavorable immune microenvironments that typically respond poorly to standard immune checkpoint inhibitors.

Other names

CXCL Chemokine and TNF Superfamily Co-stimulatory Molecule-modified Mesenchymal Stem Cells